Do 2-(Benzoyl)piperidines Represent a Novel Class of hDAT Reuptake Inhibitors?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Jones CB;Jones CB; Eltit JM; Eltit JM; Dukat M; Dukat M
  • Source:
    ACS chemical neuroscience [ACS Chem Neurosci] 2023 Feb 15; Vol. 14 (4), pp. 741-748. Date of Electronic Publication: 2023 Feb 06.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Chemical Society Country of Publication: United States NLM ID: 101525337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1948-7193 (Electronic) Linking ISSN: 19487193 NLM ISO Abbreviation: ACS Chem Neurosci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, D.C. : American Chemical Society
    • Subject Terms:
      Dopamine Uptake Inhibitors*/pharmacology ; Methylphenidate*/pharmacology; Humans ; Piperidines/pharmacology ; Dopamine Plasma Membrane Transport Proteins/genetics ; Dopamine Plasma Membrane Transport Proteins/metabolism ; Serotonin Plasma Membrane Transport Proteins/metabolism ; Biological Transport
    • Abstract:
      2-(Benzoyl)piperidines (analogues of 1a ), structural hybrids of the clinically employed ADHD medication methylphenidate ( 2 ) and the abused synthetic cathinone pentedrone ( 3 ), have been previously reported to act as novel and selective reuptake inhibitors of the human dopamine transporter (hDAT). One of the more potent benzoylpiperidines, as is the case with methylphenidate analogues, is its 3,4-dichloroaryl counterpart. Here, we demonstrate using homology models that these compounds (i.e., benzoylpiperidines and methylphenidate analogues) likely bind in a comparable manner at hDAT. In addition, it is shown here that the 3,4-dichlorobenzoylpiperidine analogue of 1a is more potent than its 3,4-dimethyl counterpart, suggesting that the electronic character of the substituents might play a role in the potency of these hybrids. Furthermore, the 3,4-benz-fused (i.e., naphthyl) benzoylpiperidine analogue acts in the same manner as its corresponding methylphenidate counterpart at hDAT. As with its methylphenidate counterpart, the naphthyl compound also acts, rather uniquely (although with lower potency) relative to other members of the two series, at the human serotonin transporter (hSERT). In conclusion, the benzoylpiperidines represent a novel structural class of hDAT reuptake inhibitors that function in a manner similar to their methylphenidate counterparts.
    • Contributed Indexing:
      Keywords: 3D molecular modeling; benzoylpiperidines; cathinones; hDAT; hSERT; methylphenidate; physiology
    • Accession Number:
      0 (Dopamine Uptake Inhibitors)
      0 (Piperidines)
      0 (Dopamine Plasma Membrane Transport Proteins)
      207ZZ9QZ49 (Methylphenidate)
      0 (Serotonin Plasma Membrane Transport Proteins)
    • Publication Date:
      Date Created: 20230206 Date Completed: 20230216 Latest Revision: 20230227
    • Publication Date:
      20231215
    • Accession Number:
      10.1021/acschemneuro.2c00666
    • Accession Number:
      36745029